The Food and Drug Administration recently announced new measures to prevent the import of dangerous foreign counterfeits of GLP-1 drug ingredients, which are being used to make unapproved compound drugs targeting individuals seeking weight loss medication.
On Sept. 5, the FDA announced the creation of a “green list” import alert for GLP-1 active pharmaceutical ingredients (APIs), according to a statement. Only GLP-1 APIs manufactured at facilities that the health agency has inspected or evaluated and found compliant with its rigorous standards will make the list, the FDA added.
Shipments from sources not on the list are “subject to detention without physical examination,” the FDA said….
FDA Announces ‘Green List’ of Foreign GLP-1 Ingredient Manufacturers
